Pirtobrutinib + Rituximab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Marginal Zone Lymphoma
Conditions
Marginal Zone Lymphoma
Trial Timeline
Feb 20, 2025 → Dec 1, 2032
NCT ID
NCT06390956About Pirtobrutinib + Rituximab
Pirtobrutinib + Rituximab is a phase 2 stage product being developed by Eli Lilly for Marginal Zone Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06390956. Target conditions include Marginal Zone Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06390956 | Phase 2 | Recruiting |
Competing Products
10 competing products in Marginal Zone Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Copanlisib + Rituximab | Celltrion | Phase 2 | 52 |
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | 52 |
| Epcoritamab | AbbVie | Phase 2 | 52 |
| Rituximab + Venetoclax | AbbVie | Phase 2 | 52 |
| VAY736 + lenalidomide | Novartis | Phase 1 | 33 |
| PI3K inhibitor BKM120 + rituximab | Novartis | Phase 1 | 33 |
| Obinutuzumab | Roche | Phase 2 | 52 |
| Umbralisib | TG Therapeutics | Phase 2 | 49 |
| HMPL-689 | HUTCHMED | Phase 2 | 47 |
| Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg | ADC Therapeutics | Phase 2 | 44 |